Precision medicine company Tempus, and diagnostic testing company LabCorp have announced a collaboration with LabCorp’s drug development business, Covance to work together to accelerate patient enrollment for oncology clinical trials. TIME Trial Network. Under the agreement, Covance will join Tempus’ TIME Trial Network, a data-driven approach that aims to improve the efficiency of clinical trials recruitment, design, and launch.
According to Tempus, the TIME Trial Networks currently consists of more than 50 provide networks encompassing more than 2,500 oncologists. Via its collaboration with Covance, Tempus aims to significantly expand its reach into oncology practices across the U.S.
“We’re excited to collaborate with LabCorp’s drug development business, Covance, and leverage their network of oncology sites and community physicians across the U.S., as well as their successful track record in executing some of the country’s most cutting-edge oncology trials,” said Kim Blackwell, chief medical officer of Tempus in a press release. “This collaboration furthers our mission to increase trial participation and ultimately bring the right treatment to the right patients at the right time.”
The TIME (Tempus Integrated Molecular Evaluation) Trial Network was launched in the spring of 2019 to recruit selected community hospitals and academic medical centers as research sites. The concept is to have a ready network of potential trial sites that can be opened quickly once appropriate patients are identified using the company’s AI-drive approach to evaluating molecular testing and data, and data contained in an individual’s electronic medical record—including the unstructured data. According to the company, its ability to examine patient data in real time allows site in the network to initiate a trial in as little as 10 days.
Creating an environment that can tap the data of thousands of patients, while having potential clinical trial sites at the ready is aimed at alleviating the difficulties of patient recruitment as biomarker-driven drug development strategies look to address smaller, more targeted patient populations.
“LabCorp’s drug development business has extensive experience in executing clinical trials and our leadership position in oncology, coupled with Tempus’ innovative clinical trial model, provides thousands of physicians and patients easier access to more therapeutics,” said Dr. Paul Kirchgraber, CEO of Covance. “With oncology patient enrollment rates being in the single digits, it’s imperative that we find comprehensive approaches to accelerate oncology clinical trials and bring new treatments to patients faster. The combination of our capabilities will increase the ability to identify patients with specific genetic markers and link them to trial sites, thus greatly expanding access to hard-to-find patient pools for faster enrollment of the right patients for precision medicine oncology clinical trials.”